Chronix news

Cancer Moonshot – Initiative of the Government of the United States

Chronix Biomedical

"The Cancer Moonshot Initiative’s mission of speeding cures for the hundreds of cancers we treat is much more complex than putting a man on the moon." President Barack Obama’s announcement of a Cancer Moonshot Initiative...

20 Years Later: A Cancer DNA Load Blood Test

Chronix Biomedical

Chronix Biomedical filed its first patent application 20 years ago on October 4, 1996. This first patent application has subsequently led to a series of exciting developments culminating in revolutionary genetic testing technology to diagnose...

#TheTurningPointInCancerFight

Chronix Biomedical

Exactly 20 years ago, on 4th of October 1996, Howard Urnovitz, founder and CEO of Chronix Biomedical, an innovative biomedical company from Palo Alto (California, US), has applied for a Patent, which was the result...

Chronix Biomedical welcomes moves to define new regulatory standards in liquid biopsy field

Chronix Biomedical

San Jose, CA, USA and Göttingen, Germany (20 July 2016) – Chronix Biomedical, Inc., a developer of blood-based molecular diagnostics, welcomes the recent moves to more clearly define US regulatory standards for the use of...

Chronix Biomedical’s serum DNA assays can monitor disease activity and treatment response in multiple sclerosis

Chronix Biomedical

San Jose, California, April 6, 2010 – Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to...

New study shows blood test detected cancer metastasis

Chronix Biomedical

RESEARCH BY CHRONIX BIOMEDICAL AND INSTITUTE OF VETERINARY MEDICINE GÖTTINGEN HIGHLIGHTS CELL-FREE DNA ANALYSIS FOR CANCER MINIMAL RESIDUAL DISEASE San Jose, CA and Göttingen, Germany—September 30, 2013—Researchers from the University Göttingen Institute of Veterinary Medicine...